ClinicalTrials.gg
RecruitingNCT06820190Updated Jan 7, 2026

Analgesic Efficacy of Multiple Mid-Transverse Process to Pleura (MTP) Block and PCA in Idiopathic Scoliosis Patients Undergoing Posterior Spinal Fusion

An interventional study of Multiple Mid-Transverse Process to Pleura (MTP) Block and Morphine in Multiple Mid-Transverse Process to Pleura, PCA and Idiopathic Scoliosis, sponsored by Tanta University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-07.

Sponsored by Tanta University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Scoliosis with a site in Egypt — 9 open to participants now, 12 under way, none of them phase 3. Scoliosis · Egypt.

Planned enrollment
9th of 17
40 · median 40
Started
2025
with 6 others
No phase
16 of 31
6 open now
Primary completion
2026-12
later than 8 of 11 live
Registered
23rd of 31
by date
Lead sponsor
3 of 31
Tanta University

Among the 31 studies in Scoliosis with a site in Egypt, this one is the 9th largest by planned enrollment of the 17 interventional ones that give a count, is one of 7 that started in 2025, is one of 16 with no phase, reaches primary completion later than 8 of the 11 other live ones, and was the 23rd registered.

Scoliosis

660 studies on the registry are indexed under Scoliosis; 185 are open to participants now.

Browse Scoliosis studies →

Open to participants now

9 of the 31 studies in Scoliosis with a site in Egypt are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 117 Scoliosis studies recruiting now, 23 (20%) set no upper age limit and 88 (75%) stop at 75 or younger; 98 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Scoliosis with a site in Egypt, or all of them as a file.
02

Study summary

This study aims to compare the analgesic efficacy of multiple mid-transverse process to pleura (MTP) block and PCA in idiopathic scoliosis patients undergoing posterior spinal fusion surgery.

Read the detailed description

The postoperative period for idiopathic scoliosis patients undergoing posterior spinal fusion (PSF) is fraught with challenges, including adequate postoperative pain control and prolonged hospitalization.

Regional anesthesia techniques, mainly epidural analgesia and, more recently, paravertebral blocks, became crucial parts of the multimodal analgesia (MMA) regimen after introducing ultrasound (US) in the regional anesthesia practice. Erector spinae plane (ESP) block and mid-transverse to pleura (MTP) block are the latest developments in postoperative pain therapy.

03

Conditions studied

  • Multiple Mid-Transverse Process to Pleura
  • PCA
  • Idiopathic Scoliosis
  • Posterior Spinal Fusion

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years.
  • Both sexes.
  • American Society of Anesthesiology (ASA) physical status I-II.
  • Idiopathic scoliosis patients undergoing posterior spinal fusion surgery.

Exclusion criteria

Exclusion Criteria:

  • Patients with pre-existing infection at block site.
  • Known allergy to study drugs.
  • Coagulation disorder.
  • History of psychiatric illness.
  • Pre-existing neurological deficits.
  • Patient with morbid obesity ( >40 kg/m2).
  • Presence of any pre-operative pain or history of chronic pain.
  • History of regular analgesic.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    MTP group

    Patients will receive multiple mid-transverse process to pleura (MTP) block after induction of anesthesia.

    Other: Multiple Mid-Transverse Process to Pleura (MTP) Block

  • Experimental
    PCA group

    Patients will receive IV-PCA. Morphine is generally administered as an initial loading dose of 0.05-0.1 mg/kg before the end of surgery, with PCA settings of a bolus dose of 0.01-0.03 mg/kg, a lockout interval of 6-10 min, and a background infusion of 0.01-0.02 mg/kg/h.

    Drug: Morphine

Interventions

  • OtherMultiple Mid-Transverse Process to Pleura (MTP) Block

    Patients will receive multiple mid-transverse process to pleura (MTP) block after induction of anesthesia.

  • Patients will receive IV-PCA. Morphine is generally administered as an initial loading dose of 0.05-0.1 mg/kg before the end of surgery, with PCA settings of a bolus dose of 0.01-0.03 mg/kg, a lockout interval of 6-10 min, and a background infusion of 0.01-0.02 mg/kg/h.

    Also known as: PCA

06

What researchers measure

Primary outcomes

  1. Degree of pain

    The degree of pain will be assessed using the Visual Analogue Scale (VAS). VAS (0 represents "no pain" while 10 represents "the worst pain imaginable"). VAS will be assessed at 0, 4, 8, 12, 18 and 24h postoperatively.

    Time frame: 24 hours postoperatively

Secondary outcomes

  1. Intraoperative fentanyl consumption

    Additional fentanyl bolus dosages of 1 µg/kg IV will be administered if heart rate or mean arterial blood pressure elevated more than 20% of the baseline (after exclusion of other causes than pain).

    Time frame: Intraoperatively

  2. Time to the first request for the rescue analgesia

    Time to the first request for the rescue analgesia (time from end of surgery to first dose of morphine administrated).

    Time frame: 24 hours postoperatively

  3. Total morphine consumption

    Postoperative analgesia was provided by morphine (3 mg IV in Multiple Mid-Transverse Process to Pleura (MTP) Block group or 0.01 mg/kg bolus with a 15-min lockout in PCA group) to keep the Visual Analogue Scale (VAS) at rest less than 4.

    Time frame: 24 hours postoperatively

  4. Mean arterial pressure

    Mean arterial pressure will be recorded preoperatively, before the block is performed, and every 15 minutes until the end of the surgery.

    Time frame: Every 15 minutes until the end of the surgery (Up to 2 hours)

  5. Heart rate

    Heart rate will be recorded preoperatively, before the block is performed, and every 15 minutes until the end of the surgery.

    Time frame: Every 15 minutes until the end of the surgery (Up to 2 hours)

  6. Degree of patient satisfaction

    Degree of patient satisfaction will be assessed on a 5-point Likert scale patient satisfaction (1, extremely dissatisfied; 2, unsatisfied; 3, neutral; 4, satisfied; 5, extremely satisfied). It will be assessed 24 hours after surgery.

    Time frame: 24 hours postoperatively

  7. Incidence of complications

    Incidence of complications such as bradycardia, hypotension, nausea, vomiting, Pruritis, respiratory depression, or any other complication will be recorded.

    Time frame: 24 hours postoperatively

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The data will be available upon a reasonable request from the corresponding author after the end of study for one year.

Supporting information: Study protocol

Time frame: After the end of study for one year.

Access criteria: The data will be available upon a reasonable request from the corresponding author.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Dec 2026, 21 months after the start.

Of 224 non-industry interventional studies with no phase under Scoliosis, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 58. This study's planned 21 months is close to that.

Counting every sponsor, half of 234 studies reached it within 22 months; a quarter within 8 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2025
First posted
Feb 11, 2025
StartActual
Feb 12, 2025
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Jan 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06820190
Lead sponsor
Tanta University
Responsible party
Mohammed Said ElSharkawy (Lecturer of Anesthesiology, Surgical Intensive Care and Pain Medicine, Faculty of Medicine, Tanta University, Tanta, Egypt., Tanta University) — Principal investigator
First posted
Feb 11, 2025
Start date
Feb 12, 2025
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Jan 7, 2026

Study contacts

Mohammed S Elsharkawy, MD
Contact
mselsharkawy@med.tanta.edu.eg
00201148207870

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Morphine

Start the discussion